Aristotle University Of Thessaloniki (AUTH)
Επίδραση των εκλεκτικών αναστολέων της κυκλοοξυγενάσης 2 στην πώρωση καταγμάτων του επίμυα
Abstract
dc:descriptionIntroduction: In the past few years numerous studies have been conducted to study the effect of traditional Non Steroid Anti-Inflammatory Drugs (NSAIDs) on the healing of fractures, and they have shown that cyclooxygenase inhibitors (COX inhibitors) prevent the healing of fractures by inhibiting prostaglandin synthesis. About two decades ago it was observed that there are two isoenzymes of cyclooxygenase COX-1 and COX-2) and that COX-2 is responsible for the inflammatory response. Based on this discovery selective inhibitors of COX-2 were developed in the past decade, which in previous studies showed a controversial effect on the healing of fractures. Aim: The purpose of this work was to study the effect of parecoxib, a new selective inhibitor of COX-2, on bone healing in rats. Parecoxib is used in injectable form for intramuscular or intravenous administration, for a short period after fracture. In our study we decided to use a treatment pattern similar to clinical treatment patterns. Materials and Methods: 120 Albino Wistar rats aged 12 weeks were used. Closed non-displaced middiaphyseal fractures in the middle of the left femoral shaft were generated in each animal. The rats were separated into three groups (A, B, C) and each group into two subgroups (Α1-Α2, Β1-Β2, C1-C2). Subgroups Α2-Β2-C2 (the study groups, 60 animals) were given parecoxib sodium 1.06mg/kg intraperitoneally for 7 days postoperatively. Subgroups Α1-Β1-C1 (the control group, 60 animals) were given normal saline intraperitoneally for 7 days postoperatively. On the 2nd, 4th and 6th week after surgery, radiographic evaluation was conducted in groups A, B and C respectively. After the mice were killed, the left femora were taken and sections from the area of the newly formed callus were studied histologically. Rats that did not meet the required radiological criteria (suitable intramedular nailing and simple transverse fracture) were excluded from the study. The SPSS package was used for the statistical study Results: At 2 weeks after fracture, radiographic signs of healing of the fracture were observed in 10% of the study group and 30% of the control group. The histologic observations in both groups were the following: osteoblasts and osteoclasts in the fracture region, fibrous connective tissue, signs of neoangiogenesis, appearance of Havers systems, appearance of chondrocytes. Fracture recovery was shown to be more advanced in some animals of the control group. At 4 weeks after fracture the percentage of fracture healing, as observed radiographically, was 60% in the study group and 80% in the control group. The histologic observations in both groups showed osteoblasts, appearance of chondrocytes, intense vascularity and some osteocytes within bone cavities. At 6 weeks after the occurrence of fracture, the radiographic imaging showed similar signs of fracture healing, namely 80% in the study group and 90% in the control group. The histologic observations in both groups were the following: appearance of ossified cartilage tissue, systems of Havers, systems of Volkmann, peripheral vascular system, bone cells in bone cavities, calcified intercellular substance and abidance of osteoblasts. The observed differences in fracture healing between the study and the control groups were not statistically significant. Conclusion: Our study is the first experimental study of parecoxib in white Wistar rats, in which we used a treatment regimen similar to that used in clinical practice and in which we studied the short and long-term effects of a short period of treatment. The results of our work show that when parecoxib is administered at a clinical dose for a short time period after bone fracture in rats, it appears to have an inhibitory effect on fracture healing, which, however seems to be transient and not to have significant long-term consequences. Further investigation is necessary, to determine whether this inhibitory effect of parecoxib on bone reconstruction is reversible in humans, and if it is safe to use parecoxib as an analgesic for bone fractures and for the relief of posttraumatic and postoperative pain in orthopaedics.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Akritopoulos, Panagiotis
- Ακριτόπουλος, Παναγιώτης
Subjects
dc:subject × 17- Πώρωση καταγμάτων
- Εκλεκτικοί αναστολείς κυκλοοξυγενάσης 2
- Παρεκοξίμπη
- Οστική επούλωση
- Αναστολείς κυκλοοξυγενάσης
- Προσταγλανδίνες
- Μη στεροειδή αντιφλεγμονώδη φάρμακα
- Fracture healing
- Selective inhibitors of cyclooxygenase-2
- Parecoxib
- Bone healing
- Prostaglandins
- Non-steroid anti-inflammatory drugs
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/22098